Oppenheimer Asset Management Inc. Buys 4,816 Shares of Thermo Fisher Scientific Inc. $TMO

Oppenheimer Asset Management Inc. grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 94,160 shares of the medical research company’s stock after acquiring an additional 4,816 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $38,178,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of TMO. CBIZ Investment Advisory Services LLC grew its position in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares during the period. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $30,000. Keystone Global Partners LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $31,000. IMA Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $37,000. 89.23% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the company’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the company’s stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 29,666 shares of company stock worth $13,990,971. 0.33% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of analyst reports. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. HSBC restated a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Citigroup boosted their price objective on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a report on Thursday. Finally, Barclays upped their price target on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday. Nineteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $595.75.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $573.07 on Friday. The company’s fifty day simple moving average is $504.04 and its 200-day simple moving average is $453.55. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The firm has a market cap of $216.40 billion, a PE ratio of 33.11, a P/E/G ratio of 3.24 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.